Please click here to obtain permission to reproduce this image.
Click on image to view larger version.
Figure 2 Impact of variations in the relative risk of death or large myocardial infarction (MI) with the GuardWire versus conventional treatment on the incremental cost-effectiveness ratio for embolic protection. Life expectancy projections for this sensitivity analysis were based on a Markov model of long-term survival contingent on 30-day rates of death or large MI after saphenous vein bypass graft percutaneous coronary intervention (Appendix). The arrow indicates the 95% confidence interval (CI) for the relative risk of death or MI based on the Saphenous Vein Graft Angioplasty Free of Emboli Randomized trial (SAFER) results (0.21 to 0.92).
|
